Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom.

Feher, Michael; Vega-Hernandez, Gabriela; Mocevic, Emina; Buysse, Brian; Myland, Melissa; Power, Geraldine S; Nystrup Husemoen, Lise L; Kim, Joseph; Witte, Daniel R

Feher, Michael; Vega-Hernandez, Gabriela; Mocevic, Emina; Buysse, Brian; Myland, Melissa; Power, Geraldine S; Nystrup Husemoen, Lise L; Kim, Joseph; Witte, Daniel R.

Afiliação

Feher M; Chelsea and Westminster Hospital, London, UK.
Vega-Hernandez G; Novo Nordisk, West Sussex, UK. gvg@novonordisk.com.
Mocevic E; Novo Nordisk, Søborg, Denmark.
Buysse B; NEMEA Centre of Excellence for Retrospective Studies, QuintilesIMS, London, UK.
Myland M; NEMEA Centre of Excellence for Retrospective Studies, QuintilesIMS, London, UK.
Power GS; NEMEA Centre of Excellence for Retrospective Studies, QuintilesIMS, London, UK.
Nystrup Husemoen LL; Novo Nordisk, Søborg, Denmark.
Kim J; NEMEA Centre of Excellence for Retrospective Studies, QuintilesIMS, London, UK.
Witte DR; Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.

Diabetes Ther ; 8(2): 417-431, 2017 Apr.

Article em En | MEDLINE | ID: mdl-28281244

Palavras-chave

GLP-1 RA; HbA1c; Liraglutide; Lixisenatide; THIN; The Health Improvement Network; Type 2 diabetes

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Observational_studies Idioma: En Revista: Diabetes Ther Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google